Journal of controlled release : official journal of the Controlled Release Society · 2013
Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stapleton Shawn, Allen Christine, Pintilie Melania, Jaffray David A
Аннотация
Liposomes have proven to be a viable drug delivery strategy resulting in significant increases in tumor accumulation of drugs via exploitation of the enhanced permeability and retention (EPR) effect. However, significant variability has been observed in their bulk tumor accumulation and intra-tumoral distribution. The heterogeneous accumulation of liposomes in solid tumors is largely believed to result from the chaotic morphology and physiology of tumor blood vessels. Thus, tumor perfusion imaging may provide a novel method to predict the accumulation and resulting therapeutic effect of liposome formulations. In this study, dynamic contrast enhanced computed tomography (DCE-CT) was employed to quantitatively estimate the intra-tumoral distribution of perfusion and anatomical CT was used to map the spatio-temporal accumulation of a CT-liposome contrast agent. A statistically significant positive correlation was found between quantitative and semi-quantitative measures of tumor perfusion (i.e. K(trans), vp, and AUC(iox)) and liposome accumulation (AUC(lipo) and C(peak)) in two mouse xenograft models of human cervical cancer. Specifically, it was found that regions with higher K(trans),vp, and AUC(iox) had greater liposome accumulation. These findings demonstrate that DCE-CT measurements of tumor perfusion may be an important technique for selecting patients that are likely to respond to liposome and potentially other nanoparticle-based therapies.